(NASDAQ: AGIO) Agios Pharmaceuticals's forecast annual revenue growth rate of 72.84% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.4%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.27%.
Agios Pharmaceuticals's revenue in 2026 is $98,338,000.On average, 12 Wall Street analysts forecast AGIO's revenue for 2026 to be $8,855,580,157, with the lowest AGIO revenue forecast at $5,207,198,148, and the highest AGIO revenue forecast at $11,789,927,657. On average, 12 Wall Street analysts forecast AGIO's revenue for 2027 to be $18,218,029,292, with the lowest AGIO revenue forecast at $7,341,540,430, and the highest AGIO revenue forecast at $26,838,981,053.
In 2028, AGIO is forecast to generate $30,972,739,363 in revenue, with the lowest revenue forecast at $16,973,245,053 and the highest revenue forecast at $52,513,178,388.